Dual specificity protein kinase
From Proteopedia
(Difference between revisions)
| Line 12: | Line 12: | ||
</StructureSection> | </StructureSection> | ||
| - | ==3D structures of dual specificity protein kinase== | ||
| - | Updated on {{REVISIONDAY2}}-{{MONTHNAME|{{REVISIONMONTH}}}}-{{REVISIONYEAR}} | ||
| - | {{#tree:id=OrganizedByTopic|openlevels=0| | ||
| - | |||
| - | *CLK1 kinase domain | ||
| - | |||
| - | **[[1z57]] – hCLK1 + himenialdizine – human | ||
| - | |||
| - | **[[5j1v]], [[5j1w]], [[2vag]], [[5x8i]], [[6raa]], [[6q8p]], [[6q8k]], [[6i5l]], [[6i5k]], [[6i5i]], [[6i5h]], [[6fyo]], [[6ft9]], [[6ft8]] – hCLK1 + inhibitor<br /> | ||
| - | **[[6g33]] – hCLK1 + iodotubercidine inhibitor<br /> | ||
| - | |||
| - | *CLK2 kinase domain | ||
| - | |||
| - | **[[3nr9]] – hCLK2<br /> | ||
| - | **[[5unp]], [[6fyl]], [[6fyk]], [[6fyi]] – hCLK2 + inhibitor<br /> | ||
| - | |||
| - | *CLK3 | ||
| - | |||
| - | **[[2eu9]] – hCLK3 | ||
| - | |||
| - | **[[2exe]] – hCLK3 kinase domain, phosphorylated | ||
| - | |||
| - | **[[2wu6]], [[2wu7]], [[6rct]], [[6fyr]], [[6fyp]], [[6ft7]] - hCLK3 kinase domain + inhibitor | ||
| - | |||
| - | **[[3raw]] - hCLK3 kinase domain + leucettine | ||
| - | |||
| - | *CLK4 kinase domain | ||
| - | |||
| - | **[[6fyv]] – hCLK4 + inhibitor<br /> | ||
| - | |||
| - | *TTK | ||
| - | |||
| - | **[[3cek]], [[3dbq]], [[2zmc]], [[6gvj]] – hTTK kinase domain<br /> | ||
| - | **[[4b94]], [[4h7x]], [[4h7y]] - hTTK TPR domain<br /> | ||
| - | **[[3gfw]] - hTTK kinase domain + pyrolo-pyridin ligand | ||
| - | |||
| - | **[[3h9f]] - hTTK kinase domain + pyrimidino-diazepin ligand | ||
| - | |||
| - | **[[2x9e]], [[3vqu]], [[3w1f]], [[4bhz]], [[4bi0]], [[4bi1]], [[4bi2]], [[4c4e]], [[4c4f]], [[4c4g]], [[4c4h]], [[4c4i]], [[4c4j]], [[4js8]], [[4jt3]], [[3wzj]], [[3wzk]], [[4o6l]], [[5ehl]], [[5eho]], [[5ehy]], [[5ei2]], [[5ei6]], [[5ei8]], [[5ap0]], [[5ap1]], [[5ap2]], [[5eh0]], [[4zeg]], [[6b4w]], [[5na0]], [[5n9s]], [[5n93]], [[5n87]], [[5n84]], [[5n7v]], [[6h3k]], [[6n6o]], [[4d2s]], [[4cva]], [[4cv9]], [[4cv8]], [[3wyy]], [[3wyx]] - hTTK kinase domain + inhibitor | ||
| - | |||
| - | **[[2zmd]], [[5ap3]], [[5ap4]], [[5ap5]], [[5ap6]], [[5ap7]], [[5o91]], [[5ntt]], [[5nad]], [[5mrb]] - hTTK kinase domain (mutant) + inhibitor<br /> | ||
| - | |||
| - | **[[3hmn]] - hTTK kinase domain + ATP | ||
| - | |||
| - | **[[3hmo]] - hTTK kinase domain + staurosporine | ||
| - | |||
| - | **[[3hmp]] - hTTK kinase domain + quinazoline ligand<br /> | ||
| - | **[[5ljj]] - hTTK kinase domain + reversine<br /> | ||
| - | }} | ||
== References == | == References == | ||
<references/> | <references/> | ||
[[Category:Topic Page]] | [[Category:Topic Page]] | ||
Revision as of 08:25, 18 June 2019
| |||||||||||
References
- ↑ Dhanasekaran N, Premkumar Reddy E. Signaling by dual specificity kinases. Oncogene. 1998 Sep 17;17(11 Reviews):1447-55. PMID:9779990 doi:http://dx.doi.org/10.1038/sj.onc.1202251
- ↑ Colombo R, Caldarelli M, Mennecozzi M, Giorgini ML, Sola F, Cappella P, Perrera C, Depaolini SR, Rusconi L, Cucchi U, Avanzi N, Bertrand JA, Bossi RT, Pesenti E, Galvani A, Isacchi A, Colotta F, Donati D, Moll J. Targeting the Mitotic Checkpoint for Cancer Therapy with NMS-P715, an Inhibitor of MPS1 Kinase. Cancer Res. 2010 Dec 15;70(24):10255-64. PMID:21159646 doi:10.1158/0008-5472.CAN-10-2101
